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ly 1, 2013.his study sought to investigate whether selective ablation of the carotid body (CB) chemoreceptors improves
cardiorespiratory control and survival during heart failure.Background Chronic heart failure (CHF) is a recognized health problem worldwide, and novel treatments are needed to better
improve life quality and decrease mortality. Enhanced carotid chemoreﬂex drive from the CB is thought to contribute
signiﬁcantly to autonomic dysfunction, abnormal breathing patterns, and increased mortality in heart failure.Methods Chronic heart failure was induced by coronary ligation in rats. Selective CB denervation was performed to remove
carotid chemoreﬂex drive in the CHF state (16 weeks post-myocardial infarction). Indexes of autonomic and
respiratory function were assessed in CB intact and CB denervated animals. CB denervation at 2 weeks post-
myocardial infarction was performed to evaluate whether early targeted CB ablation decreases the progression of
left ventricular dysfunction, cardiac remodeling, and arrhythmic episodes and improves survival.Results The CHF rats developed increased CB chemoreﬂex drive and chronic central pre-sympathetic neuronal activation,
increased indexes of elevated sympathetic outﬂow, increased breathing variability and apnea incidence, and
desensitization of the baroreﬂex. Selective CB ablation reduced the central pre-sympathetic neuronal activation by
40%, normalized indexes of sympathetic outﬂow and baroreﬂex sensitivity, and reduced the incidence of apneas in
CHF animals from 16.8  1.8 events/h to 8.0  1.4 events/h. Remarkably, when CB ablation was performed early,
cardiac remodeling, deterioration of left ventricle ejection fraction, and cardiac arrhythmias were reduced. Most
importantly, the rats that underwent early CB ablation exhibited an 85% survival rate compared with 45% survival in
CHF rats without the intervention.Conclusions Carotid chemoreceptors play a seminal role in the pathogenesis of heart failure, and their targeted ablation might
be of therapeutic value to reduce cardiorespiratory dysfunction and improve survival during CHF. (J Am Coll Cardiol
2013;62:2422–30) ª 2013 by the American College of Cardiology FoundationSee page 2431Elevated sympathetic outﬂow and breathing disorders are
2 hallmarks of chronic heart failure (CHF), and both have
been strongly related to decreased quality of life, poor
prognosis, and increased mortality (1,2). Enhanced sympa-
thetic drive and breathing instability during CHF have been
associated with alterations in peripheral and central neural
pathways that regulate autonomic function and breathing
control (3,4). Despas et al. (5) showed that CHF patients
with high peripheral chemosensitivity displayed higherIntegrative Physiology, University of Nebraska
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3; revised manuscript received June 19, 2013,sympathetic outﬂow compared with CHF patients with
normal chemosensitivity. In addition, impaired baroreﬂex
function observed in CHF has been associated with an
augmented peripheral chemosensitivity in patients with
CHF (6). Previous studies from our laboratory have
demonstrated an augmented afferent input from the carotid
body (CB) chemoreceptors in pacing-induced CHF rabbitsand myocardial-infarcted CHF rats and have shown that
reducing chemoreﬂex afferent trafﬁc results in reductions in
the sympathetic drive in CHF animals (7–9). Also, transient
inhibition of the CB chemoreﬂex with brief hyperoxic
stimulation in CHF patients results in a decreased sympa-
thetic tone (5) and an improvement in the baroreﬂex
function (6).
Patients with CHF exhibit a high incidence (up to 60%)
of breathing disorders characterized by apnea/hypopneas
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CHF = chronic heart failure
eCBD = early carotid body
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Fra-1 = Fos-related antigen 1
HRV = heart rate variability
IVS = interventricular
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medulla
JACC Vol. 62, No. 25, 2013 Del Rio et al.
December 24, 2013:2422–30 Carotid Body Denervation Improves Heart Failure Survival
2423and higher breathing variability (10,11) that have been
related to the progression of the disease (12). Exaggerated
CB-mediated ventilatory responses to apneas or hypopneas
could contribute to respiratory instability. We have previously
shown, in support of this notion, that reductions in
CB afferent activity during CHF decrease breathing variability
and apnea/hypopnea incidence in rats (13).
Together these ﬁndings suggest that the CB chemoreﬂex
sustains the cardiorespiratory dysfunction observed in CHF.
Indeed, evidence showing higher mortality rates in CHF
patients with high chemosensitivity compared with patients
with normal chemosensitivity (3) suggests a crucial role for the
CB chemoreﬂex in exacerbating the pathogenesis of CHF.
Although a causal link between exaggerated CB chemoreﬂex
drive and high mortality risk during CHF has not been
proven, sympathoexcitation and the apnea-related hypoxemia
exacerbated by the augmented chemoreﬂex could lead to an
increased arrhythmogenesis and deterioration of cardiac
function associated with a high mortality risk (2,14).
Our prior work has shown that the exaggerated che-
moreﬂex in CHF emanates from elevated tonic afferent
nerve trafﬁc from the CB (7–9). Recently, it has been
proposed that targeting the CB by denervation of the
afferent inputs might be beneﬁcial in cardiovascular
diseases exacerbated by sympathetic hyperactivity (15). The
impact of carotid body denervation (CBD) on autonomic
function and survival during CHF has not been studied
before and could represent a novel strategy to slow the
progression of cardiac deterioration and lower mortality
rates in CHF. In this study, we asked whether CBD
improves autonomic balance and breathing regularity
during CHF and whether CBD in the early stage of cardiac
dysfunction reduces cardiac remodeling and arrhythmia
incidence and increases survival of myocardial-infarcted
CHF rats.Methods
Induction of heart failure. Seventy-one (2-month-old)male
Sprague-Dawley rats, weighing between 430 and 560 g,
were studied. All animal procedures were reviewed and
approved by the Institutional Animal Care and Use
Committee of theUniversity ofNebraskaMedicalCenter and
were carried out under the guidelines of the National
Institutes of Health Guide for the Care and Use of Labo-
ratory Animals (National Institutes of Health Publication
No. 85-23, revised 1996). Chronic heart failure (CHF) was
produced by coronary artery ligation (CAL) as previously
described (13).
Selective CB denervation. At 16 weeks (Protocol 1) or 2
weeks (Protocol 2) post-CAL surgery, the rats underwent
cryogenic destruction of the CBs (16). Graphic timelines of
the protocols are provided in Online Figure 1. We found
that this surgical approach allows the elimination of the
CB chemosensory, but not the carotid baroreceptor
afferents (Online Figs. 2 and 3). The CBD did not affectwater consumption or daily food
intake (Online Fig. 4). The
sham CBD surgery performed in
sham and CHF rats showed no
cardiorespiratory effects (Online
Figs. 5 to 11).
Echocardiography. Cardiac func-
tion was determined by echocar-
diography (Vevo 770, Visualsonics,
Inc., Toronto, Ontario, Canada) as
previously described (13,17).
M-mode tracings were recorded
through the anterior and poste-
rior left ventricular (LV) walls,
and anterior and posterior wall
thicknesses (end-diastolic and end-
systolic) and LV internal dimen-
sions were measured. Rats with
ejection fractions (EFs) of <45%
were considered to be in CHF
(13,17).
Radiotelemetric monitoring of arterial blood pressure
and heart rate. At 14 weeks, rats were chronically implanted
with a radio-telemetry pressure transducer (TA11PA-C40,
DSI, St. Paul, Minnesota) with a catheter directed into the
abdominal aorta. Blood pressure (BP) and heart rate were
acquired in conscious resting state.
Autonomic balance. Heart rate variability (HRV) and the
low-frequency component of the systolic blood pressure
variability (LF-SBPV) were assessed as indirect measures of
autonomic balance (18) with power spectral analysis (19,20).
Spontaneous baroreﬂex sensitivity was assessed by spectral
calculation (21).
Arrhythmia score. Irregular heartbeats were visually
inspected from heart rate time series (22). Arrhythmic
episodes were deﬁned as premature or delayed beats with
changes >3 SDs from the mean beat-to-beat interval
duration and reported as events/h.
Evaluation of respiratory variability and ventilatory che-
moreﬂex function. Tidal volume (Vt), respiratory frequency,
and minute ventilation (Vt  respiratory frequency) were
determined by whole-body plethysmography as previously
described (13). Respiratory stability was assessed from
resting breathing recordings by Poincaré plots and analysis
of SD1 and SD2 of the interbreath interval variability (13).
Apnea and hypopnea incidence (cessation or 50%
reduction in Vt over 3 consecutive breaths) was counted
and reported as apnea and hypopnea index (events/h).
Peripheral chemoreceptors were stimulated preferentially by
allowing the rats to breathe hypoxic gas (10% oxygen/
balance nitrogen).
Western blotting. Neuronal activation in the rostral
ventrolateral medulla (RVLM) was assessed by immunoblot
of the fos-related antigen 1 (Fra-1) (1:100, Santa Cruz
Biotechnology, Dallas, Texas) in RVLM micropunches as
previously described (18). Fra-1 expression is induced during
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2424sustained neuronal activation and thus serves as a sensitive
marker of chronically activated brainstem neurons (23). The
relative amount of protein of interest was calculated as the
ratio of intensity of the band relative to the intensity of the
housekeeping gene b-actin.
Immunohistochemistry. Localization of Fra-1 immuno-
reactivity in RVLM catecholaminergic pre-sympathetic
neurons was assessed in 4% paraformaldehyde-ﬁxed
coronal sections (15 mm) of the brain. The RVLM cate-
cholaminergic pre-sympathetic neurons were identiﬁed by
immunoreactivity to tyrosine hydroxylase. Sections were
visualized with a confocal laser microscope.
Mortality and cardiac remodeling studies. In a subset of
animals, we assessed the effects of early carotid body
denervation (eCBD) (2 weeks after CAL surgery) on
survival rate and cardiac remodeling during CHF (Protocol 2)
(Online Fig. 1). Echocardiography and survival rates were
then followed through the remaining 14 weeks of the
protocol. At the end of the study, the heart was removed and
processed for histological quantiﬁcation of tissue collagen
levels from both the noninfarcted LV free wall and the
interventricular septum (IVS).
Statistics. Data are expressed as means  SEM. Differ-
ences among 3 or more groups were assessed with 1 or 2-way
analysis of variance tests, followed by Newman-Keuls or
Bonferroni post-hoc comparisons. The Student t test was
employed to compare the differences between 2 groups. The
log-rank test was used to compare survival rates between
CHF and CHFþeCBD rats. A p value <0.05 was
considered statistically signiﬁcant.Figure 1 Chemoreﬂex Function and Selective CBD in CHF
(A) Representative ventilatory recordings of the chemoreﬂex ventilatory response
to acute hypoxia (FiO2 approximately 10%) in rats with and without carotid body
denervation (CBD). (B) CBD abrogated the exaggerated hypoxic ventilatory
response in chronic heart failure (CHF) rats. VE: minute ventilation. *p < 0.05 vs.
sham; ***p < 0.001 vs. sham; þþp < 0.01 vs. CHF; þþþp < 0.001 vs. CHF.
Comparisons between groups at same FiO2. Sham/shamþCBD, n ¼ 6;
CHF/CHFþCBD, n ¼ 8.Results
Respiratory disorders and CB ablation: Protocol 1. The
CHF rats displayed cardiac chamber dilation and a signiﬁ-
cant decrease in cardiac function 16 weeks post-myocardial
infarction as described previously (13,18,24). Echocardio-
graphic parameters were measured in sham and CHF rats
(Online Table 1). The CHF rats exhibited reduced EF and
fractional shortening (<40% of normal values) compared
with noninfarcted sham rats (p < 0.05). Infarct size was
38  2% of the total LV area in CHF rats (24).
Sixteen weeks after infarct surgery, rats developed
a signiﬁcant increase in CB chemoreﬂex drive as evidenced by
increased normoxic ventilation (Online Table 2) and poten-
tiation of the hypoxic ventilatory response (Figs. 1A and 1B,
Online Fig. 5). The CHF rats displayed breathing disorders
at rest (Figs. 2A and 2B). Breath-to-breath (SD1) and
aggregate (SD2) breathing variability in CHF-rats increased
2-fold compared with the values obtained from sham rats
(Figs. 2C and 2D). In addition, CHF rats displayed a greater
number of apneas and hypopneas (Fig. 2E) compared with
that in sham rats (16.8  1.8 events/h vs. 8.0  1.4 events/h,
CHF vs. sham). The increased apnea index in CHF rats was
not associated with post-sigh events, which remained
unchanged (Online Fig. 7).The elevated resting ventilation and the enhanced venti-
latory response to hypoxia in CHF rats were markedly
reduced after CBD to values similar to sham rats that
underwent CBD (Fig. 1B, Online Fig. 5). Moreover,
breathing variability was normalized in CHF-CBD rats
(Fig. 2). After CBD, both SD1 and SD2 interbreath vari-
ability were signiﬁcantly reduced (53.4% and 57.2%,
respectively) compared with the values obtained before CBD
in CHF rats (Figs. 2C and 2D). The CBD also signiﬁcantly
Figure 2 Selective CBD Restored Normal Breathing Control in CHF
(A) Representative tracings of tidal volume (Vt) and arterial blood pressure (BP) taken at rest in a sham and CHF rat before and after CBD. Breathing instability is shown in the Vt
tracings from the CHF rat, and CBD restored normal breathing rhythm. (B) Poincaré plots showing the breath-to-breath (BB) interval variability in the same rats illustrated in A.
(C) CBD reduced SD1 (short-term variability) and (D) SD2 (long-term variability) of the breathing interval in CHF rats. **p < 0.01 vs. sham; ***p < 0.001 vs. sham; þþp < 0.01
vs. CHF; þþþp < 0.001 vs. CHF. (E) CBD suppressed the apnea–hypopnea incidence (AHI) in CHF rats. ***p < 0.001 vs. sham; þþp< 0.01 vs. CHF. Sham/shamþCBD, n¼ 6;
CHF/CHFþCBD, n ¼ 8. Abbreviations as in Figure 1.
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2425decreased apnea and hypopnea index in CHF rats (Fig. 2E)
to the level seen in sham rats (Fig. 2E).
Cardiac autonomic control after CBD in CHF rats.
Autonomic imbalance was evident in CHF rats compared
with sham rats (Fig. 3). A shift in the HRV toward
augmented sympathetic drive was found during CHF
(Figs. 3B to 3D) as evidenced by a 2-fold increase in the
low- to high-frequency ratio of the HRV compared with
sham rats (Fig. 3B). A major component to this shift was
a signiﬁcant reduction in the parasympathetic respiratory
sinus arrhythmia during CHF as evidenced by a signiﬁcantdecrease in the high-frequency component of the HRV
(Fig. 3D).
Ablation of the CB rescued normal HRV in CHF rats
(Fig. 3, Online Fig. 8). The low- to high-frequency ratio of
the HRV signiﬁcantly decreased from 2.0  0.3 to 0.9  0.2
(before and after CBD, respectively, p < 0.05) in rats with
CHF. Selective CBD did not affect resting BP or heart rate
in either shamþCBD or CHFþCBD rats (Online Table 2).
Carotid chemoreceptor ablation and brainstem pre-
sympathetic neuronal activation during CHF. Catecho-
laminergic pre-sympathetic neurons (Fig. 4A) located in the
Figure 3 Selective CBD Normalized Cardiac Autonomic Balance in CHF
(A) Representative traces of the power spectral density (PSD) of heart rate variability (HRV) in sham, shamþCBD, CHF, and CHFþCBD rats. CHF rats displayed a marked
increase in the low-frequency (LF) component of the PSD and a decrease in the high-frequency (HF) component. (B) CBD markedly reduced low-frequency/high-frequency ratio
(LF/HF) in CHF rats. (C) The LF band expressed in normalized units (n.u.) and (D) the HF band expressed in n.u. *p < 0.05 vs. sham; þp < 0.05 vs. CHF. Sample size as in
Figure 2. Abbreviations as in Figure 1.
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regulation of sympathetic outﬂow during CHF (25). After
CHF, RVLM catecholaminergic neurons (tyrosine
hydroxylase-positive) exhibited a 40% increase in Fra-1
immunoreactivity, a marker of chronic neural activation,
compared with sham rats (Figs. 4A to 4C). By contrast,
selective CBD signiﬁcantly reduced Fra-1 expression in
CHF rats (1.5  0.1 vs. 0.9  0.1 normalized unit, CHF vs.
CHFþCBD) to levels comparable to the values obtained in
sham rats (Fig. 4).
Sympathovasomotor tone and baroreﬂex gain after CBD.
Sympathovasomotor tone as estimated by the LF-SBPV
increased in CHF rats, which was normalized (from
18.4  4.5 mm Hg2 to 7.2  2.0 mm Hg2) after CBD
(Online Fig. 9A). In addition, the impaired baroreﬂex
sensitivity displayed by CHF rats was signiﬁcantly improved
after CBD (Online Fig. 9B).
Progression of cardiac remodeling and arrhythmogenesis
after eCBD in CHF: Protocol 2. Necrotic myocytes in the
infarct region were almost completely replaced with ﬁbrotic
scar tissue 16 weeks after CAL surgery in both CHF and
CHF-eCBD rats (Fig. 5A). In addition, both groups
exhibited nearly identical infarct sizes (Online Fig. 11).
Nevertheless, we hypothesized that restoration of autonomic
control and breathing regularity by eCBD, 2 weeks afterCAL, would inﬂuence remodeling in the noninfarcted
regions.
Noninfarcted cardiac tissue from CHF rats displayed
a signiﬁcant 4.5-fold increase in the LV free wall and a 3-fold
increase in the IVS collagen deposition compared with sham
hearts (Fig. 5B). Notably, collagen content was reduced in
noninfarcted cardiac tissue from CHF-eCBD rats (Figs. 5C
and 5D), which was indistinguishable from the LV free wall
and IVS collagen content obtained in sham rats. Analo-
gously, the incidence of arrhythmias was markedly increased
in CHF rats compared with sham rats (Fig. 6), and CHF-
eCBD decreased the arrhythmic episodes 2.5-fold
compared with the CHF group (Fig. 6B).
Both CHF and CHFþeCBD groups had comparable
EFs before CBD was performed at 2 weeks after CAL
(Online Table 3), but the progressive deterioration of EF in
CHF-eCBD rats was blunted over the remaining 14-week
period compared with CHF rats (Fig. 7A). A diminished
expansion of LV systolic volume accompanied the preser-
vation of EF in CHF-eCBD rats (52.5  16.6% vs. 98.0 
12.0% increase, CHF-eCBD vs. CHF, p < 0.05). The
increase in LV diastolic volume also tended to be smaller
in CHF-eCBD rats (37  12% vs. 61  10% increase,
CHF-eCBD vs. CHF) but was not statistically signiﬁcant
(p ¼ 0.14).
Figure 4 Selective CBD Reduced Pre-Sympathetic Neuron Activation in CHF
(A) The number of activated catecholaminergic neurons (arrow, yellow) in the rostral ventrolateral medulla were increased in CHF rats and reduced in CHF-CBD rats. Note that
not all tyrosine hydroxylase (TH) positive cells (green) displayed fos-related antigen 1 (Fra-1) immunostaining (arrowhead). Individual neurons are shown by nuclear stain, dapi
(blue), catecholaminergic neurons by TH expression (green), and activated neurons by Fra-1 expression (red). Activated catecholaminergic neurons (co-expressing TH and Fra-1
(yellow), were identiﬁed by merging color images. (B) Expression of Fra-1 protein in RVLM micropunches. All lanes were run on the same blot. (C) Quantitative analysis of
Fra-1 expression. CBD signiﬁcantly reduced Fra-1 expression in pre-sympathetic neurons from CHF rats as shown in A. b actin protein served as the gel loading control.
***p < 0.001 vs. sham; þþþp < 0.001 vs. CHF, n ¼ 6 rats/group. Abbreviations as in Figure 1.
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mortality rate in CHF rats (p ¼ 0.04) over the 14 weeks
post-infarct compared with CHF rats with the CB intact
(85% vs. 45% survival, CHF-eCBD vs. CHF) (Fig. 7B).
Discussion
The present study unveils a major role of the CB chemoreﬂex
in the pathophysiology of heart failure. Here, we show for the
ﬁrst time to our knowledge that selective CBD normalizes
control of breathing, reduces pre-sympathetic neuronal
activation in the RVLM in the brainstem, and restores
normal autonomic and baroreﬂex function in CHF rats.
Notably, CBD performed early after myocardial infarction
results in signiﬁcant reductions in aberrant ventricular
remodeling and incidence of arrhythmias and reduces the
progressive deterioration of LV function. The outcome is
that selective CBD improves survival in CHF rats.
Cardiac deterioration andmortality during the progression
of heart failure. Autonomic dysfunction, breathing
disorder, myocardial remodeling, and arrhythmogenesis
constitute major predictors of morbidity and mortality in
CHF (2,14,26–28). We have shown that CBD reduces
sympathetic activation, respiratory instability, myocardial
ﬁbrosis, arrhythmias, and mortality during CHF. Moreover,
our data strongly suggest that the effects of CBD are
primarily associated with a normalization of altered central
neural control of cardiovascular and ventilatory function
arising from elevated input from the CB.Selective CBD and cardiac remodeling during heart
failure. Although the present results suggest a seminal role of
the CB in cardiac remodeling and progression of the disease,
the molecular signaling pathways in the heart affected by
CBD remain to be elucidated. Nevertheless, we can speculate
that the effects ofCBDon cardiac remodeling are likely due, at
least in part, to a reduced sympathetic input and increased
parasympathetic input to the heart. Indeed, it is well known
that maladaptive heightened sympathetic/reduced para-
sympathetic outﬂow to the heart after myocardial infarction
constitutes a major component in the progression into CHF
(1,3,7,29). Moreover, it has been proposed that the mecha-
nism underlying cardiac deterioration is associated with
neurohumoral activation and increased catecholamines release
by cardiac sympathetic nerve terminals during augmented
sympathetic drive in CHF (30,31). Also, although CBD
markedly improved cardiac systolic function and survival
during CHF, it did not alter LV chamber dilation and
hypertrophy (Online Table 3). Clearly, other factors continue
to play an important role in cardiac tissue remodeling after
myocardial infarction that are not affected by CBD.
Selective CBD and sympathetic activation in heart
failure. Activation of the RVLM is a critical component in
the regulation of sympathetic outﬂow during CHF (17). We
found that CBD decreases pre-sympathetic neuronal acti-
vation in the RVLM in CHF. Thus, it is reasonable to
assume that CBD resulted in a general decrease in sympa-
thetic outﬂow in the CHF rats, although the extent to
speciﬁc vascular beds cannot be ascertained directly.
Figure 5 eCBD Reduced Cardiac Fibrosis in CHF
(A) Rats with CHF and with CHF þ early carotid body denervation (eCBD) displayed left ventricle (LV) dilation and tissue ﬁbrosis in the infarcted region at 16 weeks post-infarct.
(B)Marked collagen deposition was evident in the LV free wall and the interventricular septum (IVS) from CHF. Selective eCBD signiﬁcantly reduced cardiac ﬁbrosis in the LV-free
wall (B, C) and in the IVS (B to D). ***p < 0.01 vs. sham; þþþp < 0.001 vs. CHF, n ¼ 4 rats/group. Abbreviations as in Figure 1.
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mogenesis after CBD are consistent with a reduction in
sympathetic outﬂow to the heart.
Besides the direct beneﬁcial effects of CBD to reduce
sympathetic activation of the heart during CHF, the
reduction in sympathetic outﬂow might indirectly beneﬁt
the heart by impacting vascular peripheral resistance to
decrease cardiac afterload and the kidneys to improve renal
function and blood volume homeostasis. In support of
improved afterload, we observed a trend (but not statistically
signiﬁcant) toward decreased BP after CBD (Online
Table 4). In addition, CBD decreased LF-SBPV, suggest-
ing that CBD might have decreased vasomotor tone in CHF
rats. We did not assess renal function in this study; however,
it is well known that sympathoexcitation impairs
renal function in CHF (32). The impact of CBD on
hemodynamic status and renal function during the
progression of CHF warrants further study.Selective CBD and breathing in heart failure. The inci-
dence of breathing disorders is high in patients with CHF
(10–12), and the incidence of periodic breathing and
Cheyne-Stokes respiration is associated with a deterioration
of cardiac function (12). Remarkably, CBD reduced
breathing variability and diminished the occurrence of apnea
episodes in CHF rats, which supports a role for the CB in
the generation of abnormal breathing patterns observed
during CHF. The central neural mechanisms underlying
induction of breathing instability by the CB in CHF deserve
further study.
Clinical implications. Despite the current advances in the
treatment of heart diseases, mortality rates during CHF are
still high (33). The progressive deterioration of cardiac func-
tion during CHF encompasses complex pathophysiological
mechanisms that are resistant to treatment by a single thera-
peutic intervention. Breathing disorders and heightened
sympathetic outﬂow are 2 major hallmarks of CHF, and both
Figure 7
eCBD Delayed Cardiac Deterioration and
Improved Survival in CHF
(A) Selective eCBD blunted the deterioration in the ejection fraction (EF) during
CHF (expressed as % of the EF values obtained at 2 weeks post-CAL surgery before
CBD). þp < 0.01 vs. CHF. (B) Early CBD improved survival rate in CHF rats
compared with those with intact CBs (p ¼ 0.04). Abbreviations as in Figures 1, 5,
and 6.
Figure 6 Early CBD Reduced Arrhythmic Episodes in CHF
(A) Tracings show arrhythmic episodes in a CHF rat and a marked decreased in the
arrhythmic events in a CHFþeCBD rat. (B) Arrhythmia incidence was increased in
CHF and signiﬁcantly reversed by eCBD at 16 weeks post-coronary artery ligation
(CAL). *p < 0.05 vs. sham; þp< 0.05 vs. CHF, n¼ 4 rats/group. Abbreviations as
in Figures 1 and 5.
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(1,2,5,6). Furthermore, cardiac remodeling and increases in
cardiac arrhythmogenesis are both recognized to contribute to
the progression of CHF. Our current ﬁndings indicate that
targeted ablation of the CB is a potentially valuable therapeutic
strategy that can effectively reverse autonomic and respiratory
dysfunction and improve survival of CHF. Excitingly, a recent
case report presented by Niewinski et al. (34) showed that
surgical removal of the CB from a patient with systolic heart
failure signiﬁcantly decreased sympathetic tone. Thus, our
results showing the more extensive beneﬁcial effects of ablation
of the CB should be relevant and potentially transferrable to
humans.Conclusions
The present study reports a major role of the CB chemo-
reﬂex in the cardiorespiratory alterations after CHF and
shows that selective ablation of the CB effectively restores
normal control of breathing and autonomic and baroreﬂex
function during CHF. Furthermore, when performed earlier
during the progression of CHF, selective CB ablation
improves survival. Taken together, targeted CBD showspromise as a novel therapeutic strategy to improve auto-
nomic control of the heart, decrease cardiac remodeling,
reduce the incidence of arrhythmias, and increase life span in
heart failure patients. Additionally, selective CB ablation
might also have important implications for the treatment of
breathing abnormalities during heart failure.
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APPENDIX
For an expanded Methods section as well as supplemental tables and
ﬁgures, please see the online version of this article.
